Drug Information

Drug General Information
Drug ID
D0N5YA
Former ID
DAP000133
Drug Name
Repaglinide
Synonyms
Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
Drug Type
Small molecular drug
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Approved [538328], [541921]
Therapeutic Class
Hypoglycemic Agents
Company
Novo Nordisk
Structure
Download
2D MOL

3D MOL
Formula
C27H36N2O4
InChI
InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
InChIKey
FAEKWTJYAYMJKF-QHCPKHFHSA-N
CAS Number
CAS 135062-02-1
PubChem Compound ID
65981
PubChem Substance ID
9872, 7847660, 7980507, 8190080, 11112894, 11467074, 11468194, 11486642, 12014667, 14808699, 14833410, 24724596, 26719812, 43122707, 46386564, 46508150, 47425572, 48244693, 48319772, 48395177, 48416511, 49648522, 49699266, 49888451, 50100536, 52108264, 53789672, 57315871, 81092844, 85788088, 92125938, 92308165, 92308498, 92719265, 93166496, 99218180, 99431925, 99437146, 103394824, 103914669, 104041348, 104179029, 104335174, 117545849, 117873275, 121363609, 124659000, 124757239, 124799919, 125164043
SuperDrug ATC ID
A10BX02
SuperDrug CAS ID
cas=135062021
Target and Pathway
Target(s) Sulfonylurea receptor 1 Target Info Blocker [535457], [535492], [537390]
SUR2-type K(ATP) channel Target Info Blocker [535457], [535492], [537390]
KEGG Pathway ABC transporters
Insulin secretion
Type II diabetes mellitus
Pathway Interaction Database FOXA2 and FOXA3 transcription factor networks
PathWhiz Pathway Muscle/Heart Contraction
Pancreas Function
Reactome ABC-family proteins mediated transport
Regulation of insulin secretion
WikiPathways Potassium Channels
Integration of energy metabolism
References
Ref 538328FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077571.
Ref 541921(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6841).
Ref 535457Pharmacological modulation of K(ATP) channels. Biochem Soc Trans. 2002 Apr;30(2):333-9.
Ref 535492Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41(7):471-83.
Ref 537390Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.